After grouping based on different clinical characteristics, we found that SLC16A4 expression was significantly associated with gender, tumor invasion depth (M), lymph node metastasis (N), distant metastasis (T), tumor stage, and smoking history in lung cancer patients (Table 2). Here, SLC16A4 is linked to lung carcinoma.